<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232804</url>
  </required_header>
  <id_info>
    <org_study_id>01290402</org_study_id>
    <nct_id>NCT00232804</nct_id>
  </id_info>
  <brief_title>The BRIDGE Registry: Safety and Efficacy Registry of Bx Cypher Stent</brief_title>
  <official_title>Safety and Efficacy Registry of Bx Cypher Stent in the Revascularisation of Patients With Significant Risk of Restenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to establish the safety and efficacy of the treatment with&#xD;
      Cypher DES in diabetic patients with documented ischemia due to stenosis (small coronary&#xD;
      artery 2.5 -3 mm in lumen diameter, with lesion between 15 mm 30 mm in length, ) in native&#xD;
      coronary arteries.&#xD;
&#xD;
      The objective of this study is to document that the use of Cypher DES in these diabetic&#xD;
      patients undergoing percutaneous revascularization for stenosis is safe.&#xD;
&#xD;
      Safety will be assessed over a period of 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, comparative, non randomised, open registry of 1000&#xD;
      patients who will be followed up to 12 months at 100 sites in France.&#xD;
&#xD;
      Patients will be screened according to normal practice and in relation to the inclusion and&#xD;
      exclusion criteria. Patients should have a documented ischemia related to the target vessel.&#xD;
&#xD;
      Procedure of stent placement should be done under existing in hospital procedural protocol&#xD;
      and care should be taken to follow Cordis instructions as set forth in the Instructions For&#xD;
      Use.&#xD;
&#xD;
      Follow up will be done according to normal procedure and the minimum should be a telephone&#xD;
      contact at 1, 6 and 12 months.&#xD;
&#xD;
      All data gathered during the enrollment, procedure, follow up and when specific events to the&#xD;
      patient may occur, will be entered into the Internet CRF form, by the treating physician or a&#xD;
      person from his staff specifically appointed to this task.&#xD;
&#xD;
      Patient enrollment is anticipated to last 8 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE.</measure>
    <time_frame>1, 6, and 12 months post-procedure</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">639</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bx Cypher stent</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. NIDDM treated with oral antidiabetics for at least 3 months, or IDDM treated for at&#xD;
             least 3 months with documented HbA1C;&#xD;
&#xD;
          2. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society&#xD;
             Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald&#xD;
             Classification B I-II) OR patients with documented silent ischemia;&#xD;
&#xD;
          3. Target lesion stenosis is &gt;50% (visual estimate);&#xD;
&#xD;
          4. Target vessel diameter, between 2.5 and 3.0 mm&#xD;
&#xD;
          5. Target lesion length minimum 15 mm and maximum 30mm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. CK and CK-MB enzymes above normal or elevated troponin level (as determined by site&#xD;
             criteria) at the time of treatment;&#xD;
&#xD;
          2. Has unstable angina classified as Braunwald III B and A or C I-II-III, or is having a&#xD;
             peri-infarction;&#xD;
&#xD;
          3. Unprotected left main coronary disease with &gt;=50% stenosis;&#xD;
&#xD;
          4. Significant (&gt;50%) stenosis proximal or distal to the target lesion that might impede&#xD;
             inflow or runoff and can not be revascularized before or during the index procedure;&#xD;
&#xD;
          5. Have an ostial target lesion;&#xD;
&#xD;
          6. Documented left ventricular ejection fraction &lt;=30%;&#xD;
&#xD;
          7. In-Stent restenosis;&#xD;
&#xD;
          8. Chronic total occlusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lablanche, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Lille, Hôpital cardiologique</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Université de Lille, Hôpital cardiologique</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Lablanche JM, Commeau P; Investigateurs du Registre BRIDGE. [BRIDGE registry (safety and efficacy registry Bx Cyper stent in the RevascularIzation of patients with siGnificative risk of rEstenosis): protocol description and preliminary results]. Ann Cardiol Angeiol (Paris). 2004 May;53 Suppl 1:29s-31s. French.</citation>
    <PMID>15291158</PMID>
  </results_reference>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2005</study_first_posted>
  <last_update_submitted>October 8, 2007</last_update_submitted>
  <last_update_submitted_qc>October 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

